2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-
| Title | Journal |
|---|---|
| The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. | Bone 20130301 |
| Targeted therapy for breast cancer prevention. | Frontiers in oncology 20130101 |
| The evolution of selective estrogen receptor modulators in osteoporosis therapy. | Climacteric : the journal of the International Menopause Society 20121201 |
| Preventive therapy for breast cancer. | Current oncology reports 20121201 |
| Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. | Pathology oncology research : POR 20121001 |
| Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol. | Chemical research in toxicology 20120716 |
| Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. | Bone 20120501 |
| An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. | Maturitas 20120301 |
| Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120201 |
| Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. | Menopause (New York, N.Y.) 20120101 |
| Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. | International journal of women's health 20120101 |
| Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging. | Frontiers in endocrinology 20120101 |
| Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications. | PloS one 20120101 |
| Progress in endocrine approaches to the treatment and prevention of breast cancer. | Maturitas 20111201 |
| Effects of antiresorptive treatment on nonvertebral fracture outcomes. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111001 |
| The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. | Breast (Edinburgh, Scotland) 20111001 |
| Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. | Calcified tissue international 20110801 |
| Selective estrogen receptor modulators: the future in menopausal treatment. | Minerva ginecologica 20110601 |
| Preventive therapy for breast cancer: a consensus statement. | The Lancet. Oncology 20110501 |
| Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. | The Annals of pharmacotherapy 20110401 |
| New and emerging antiresorptive treatments in osteoporosis. | Current drug safety 20110401 |
| Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. | Expert opinion on drug discovery 20110201 |
| Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. | Menopause (New York, N.Y.) 20110101 |
| The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. | Menopause (New York, N.Y.) 20110101 |
| Prevention of breast cancer by newer SERMs in the future. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis. | Arthritis research & therapy 20110101 |
| Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. | Clinical interventions in aging 20110101 |
| Lasofoxifene in osteoporosis and its place in therapy. | Advances in therapy 20101201 |
| Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. | Journal of the National Cancer Institute 20101117 |
| Tipping the balance for the primary prevention of breast cancer. | Journal of the National Cancer Institute 20101117 |
| Third-generation SERMs may face uphill battle. | Journal of the National Cancer Institute 20101117 |
| What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101101 |
| Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. | Circulation 20101026 |
| Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101001 |
| New selective estrogen receptor modulators (SERMs) in development. | Current osteoporosis reports 20100901 |
| Therapeutics. Lasofoxifene reduced vertebral fractures in postmenopausal women with osteoporosis. | Annals of internal medicine 20100720 |
| Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of 'Lasofoxifene in postmenopausal women with osteoporosis'. N Engl J Med 2010;362:686-96. | Expert opinion on pharmacotherapy 20100701 |
| Lasofoxifene for postmenopausal women with osteoporosis. | The New England journal of medicine 20100610 |
| Lasofoxifene for postmenopausal women with osteoporosis. | The New England journal of medicine 20100610 |
| Lasofoxifene for postmenopausal women with osteoporosis. | The New England journal of medicine 20100610 |
| An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. | Molecular endocrinology (Baltimore, Md.) 20100401 |
| SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. | Arquivos brasileiros de endocrinologia e metabologia 20100301 |
| Lasofoxifene in postmenopausal women with osteoporosis. | The New England journal of medicine 20100225 |
| Another selective estrogen-receptor modulator for osteoporosis. | The New England journal of medicine 20100225 |
| Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. | The Journal of steroid biochemistry and molecular biology 20100101 |
| Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. | Menopause (New York, N.Y.) 20100101 |
| Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. | Clinical interventions in aging 20100101 |
| Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. | BMC musculoskeletal disorders 20100101 |
| Modulators of androgen and estrogen receptor activity. | Critical reviews in eukaryotic gene expression 20100101 |
| A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. | Bone 20091201 |
| Lasofoxifene: new drug. Osteoporosis: no better than raloxifene. | Prescrire international 20091201 |
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. | Journal of women's health (2002) 20091001 |
| Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. | Expert opinion on pharmacotherapy 20090901 |
| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. | Annals of oncology : official journal of the European Society for Medical Oncology 20090801 |
| New selective estrogen and androgen receptor modulators. | Current opinion in rheumatology 20090701 |
| Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. | Endocrinology 20090401 |
| Designing the ideal selective estrogen receptor modulator--an achievable goal? | Menopause (New York, N.Y.) 20090101 |
| Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. | Bioinformation 20090101 |
| Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. | Therapeutics and clinical risk management 20090101 |
| Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. | Climacteric : the journal of the International Menopause Society 20090101 |
| Progress in osteoporosis and fracture prevention: focus on postmenopausal women. | Arthritis research & therapy 20090101 |
| Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. | Therapeutics and clinical risk management 20090101 |
| Lasofoxifene: Evidence of its therapeutic value in osteoporosis. | Core evidence 20090101 |
| Recent advances in managing osteoporosis. | F1000 medicine reports 20090101 |
| Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. | International journal of women's health 20090101 |
| Bazedoxifene for the prevention of postmenopausal osteoporosis. | Therapeutics and clinical risk management 20081201 |
| Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. | The Journal of steroid biochemistry and molecular biology 20081101 |
| Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. | Drug metabolism and disposition: the biological fate of chemicals 20080901 |
| Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). | American journal of obstetrics and gynecology 20080801 |
| Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. | Drug metabolism and disposition: the biological fate of chemicals 20080701 |
| Hormone-dependent aging problems in women. | Yonsei medical journal 20080630 |
| Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. | Molecular and cellular endocrinology 20080611 |
| Selective estrogen receptor modulators: an update on recent clinical findings. | Obstetrical & gynecological survey 20080301 |
| Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424. | Drugs in R&D 20080101 |
| [Status of novel bone-targeting SERMs in development]. | Nihon rinsho. Japanese journal of clinical medicine 20071128 |
| In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. | PLoS computational biology 20071101 |
| Validation of a dissolution method with HPLC analysis for lasofoxifene tartrate low dose tablets. | Journal of pharmaceutical and biomedical analysis 20070903 |
| Effect of estrogens on skin aging and the potential role of SERMs. | Clinical interventions in aging 20070901 |
| Update on bazedoxifene: a novel selective estrogen receptor modulator. | Clinical interventions in aging 20070901 |
| The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene. | Protein science : a publication of the Protein Society 20070501 |
| The future of the new selective estrogen receptor modulators. | Menopause international 20070301 |
| Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. | British journal of clinical pharmacology 20070101 |
| Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys. | Menopause (New York, N.Y.) 20070101 |
| Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. | Drugs & aging 20070101 |
| Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. | Expert opinion on investigational drugs 20060901 |
| Management of age-related osteoporosis and prevention of associated fractures. | Therapeutics and clinical risk management 20060901 |
| Developments in the pharmacotherapeutic management of osteoporosis. | Expert opinion on pharmacotherapy 20060801 |
| Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women. | Journal of clinical pharmacology 20060601 |
| Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. | British journal of clinical pharmacology 20060601 |
| Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. | Drugs of today (Barcelona, Spain : 1998) 20060601 |
| Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. | The Annals of pharmacotherapy 20060101 |
| A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. | Journal of clinical pharmacology 20060101 |
| Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. | Journal of clinical pharmacology 20060101 |
| [Next generation selective estrogen receptor modulators]. | Clinical calcium 20060101 |
| Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. | Drugs 20060101 |
| Estrogen receptors as therapeutic targets in breast cancer. | Current topics in medicinal chemistry 20060101 |
| Not all SERMs are created equal. | Menopause (New York, N.Y.) 20060101 |
| Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. | Menopause (New York, N.Y.) 20060101 |
| Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. | Menopause (New York, N.Y.) 20060101 |
| Not all selective estrogen response modulators are created equal: update on lasofoxifene. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). | Breast cancer research : BCR 20060101 |
| Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms. | Bioorganic & medicinal chemistry letters 20051201 |
| Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. | Journal of clinical pharmacology 20051201 |
| A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201 |
| Lasofoxifene (Pfizer). | Current opinion in investigational drugs (London, England : 2000) 20051001 |
| Urogenital effects of selective estrogen receptor modulators: a systematic review. | Climacteric : the journal of the International Menopause Society 20050901 |
| Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. | Biology of reproduction 20050401 |
| Estrogen receptor ligands. Part 11: Synthesis and activity of isochromans and isothiochromans. | Bioorganic & medicinal chemistry letters 20050201 |
| Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. | Journal of medicinal chemistry 20050127 |
| Lasofoxifene: CP 336156, CP-336156. | Drugs in R&D 20050101 |
| Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? | Breast cancer research : BCR 20050101 |
| Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. | Journal of neurobiology 20041101 |
| [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. | Clinical calcium 20041001 |
| Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. | Birth defects research. Part B, Developmental and reproductive toxicology 20040601 |
| Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats. | Birth defects research. Part B, Developmental and reproductive toxicology 20040601 |
| Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. | Birth defects research. Part B, Developmental and reproductive toxicology 20040601 |
| Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. | Birth defects research. Part B, Developmental and reproductive toxicology 20040601 |
| Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. | Endocrinology 20040401 |
| Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. | The Journal of steroid biochemistry and molecular biology 20030701 |
| Novel therapies for osteoporosis. | Expert opinion on investigational drugs 20030401 |
| SERMs: current status and future trends. | Critical reviews in oncology/hematology 20020701 |
| Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. | Clinical breast cancer 20020101 |
| LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. | Cancer research 20011215 |
| Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20010401 |
| Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000. | Breast cancer research : BCR 20010101 |
| Chemical and biochemical issues related to X-ray crystallography of the ligand-binding domain of estrogen receptor alpha. | Bioconjugate chemistry 20010101 |